Syndax Pharmaceuticals reported a combined $34 million in net sales for its products Revuforj and Niktimvo in the first quarter of 2025. Revuforj, in its first full quarter of launch, generated $20.0 million in net revenue, while Niktimvo, in its first partial quarter, generated $13.6 million in net revenue reported by Incyte. The company ended the quarter with $602.1 million in cash, cash equivalents, and investments, which is expected to fund operations to profitability.

Syndax Pharmaceuticals saw its first product revenue of $7.7M from Revuforj in Q4 2024, following its launch in November. However, the company reported a net loss of $94.2M, reflecting high R&D and SG&A expenses. The company maintains a strong cash position of $692.4M, which is expected to fund operations until profitability.

Syndax reported its Q3 2024 financial results, highlighting the transition to a commercial-stage company with the approval of Niktimvo and a royalty financing agreement expected to fund the company through profitability.

Syndax Pharmaceuticals reported its Q2 2024 financial results, highlighting the advancement of its pipeline and the upcoming PDUFA action dates for axatilimab and revumenib.

Syndax Pharmaceuticals reported its financial results for the quarter ended March 31, 2024. The company highlighted the potential near-term approvals of revumenib and axatilimab, as well as pivotal data expected from the AUGMENT-101 trial in the fourth quarter. The company had cash, cash equivalents, and short and long-term investments of $522.0 million as of March 31, 2024.

Syndax Pharmaceuticals reported a net loss attributable to common stockholders of $72.5 million, or $1.00 per share, for the three months ended December 31, 2023. The company's cash and cash equivalents are expected to provide runway through 2026.

Syndax Pharmaceuticals reported its financial results for the quarter ended September 30, 2023. The company continues to advance its pipeline, with NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia and plans to submit a BLA filing for axatilimab by year-end 2023.

Syndax Pharmaceuticals reported its financial results for Q2 2023, highlighting positive data from the AGAVE-201 trial of axatilimab and progress with the AUGMENT-101 trial of revumenib. Two U.S. registrational filings are expected by the end of 2023.

Syndax Pharmaceuticals reported its financial results for the quarter ended March 31, 2023. The company is expecting two U.S. registrational filings by the end of 2023. Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD is on track for mid-2023, and topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia is on track for the third quarter of 2023.

Syndax Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2022. The company had cash, cash equivalents, short-term and long-term investments of $481.3 million as of December 31, 2022. Two U.S. registrational filings are expected by the end of 2023.

Syndax Pharmaceuticals reported its Q3 2022 financial results, highlighting positive data from the AUGMENT-101 trial of revumenib and the completion of enrollment in the pivotal AGAVE-201 trial of axatilimab. The company is on track for two U.S. registrational filings by the end of 2023.

Syndax Pharmaceuticals reported its financial results for the second quarter ended June 30, 2022. Key highlights include advancements in the clinical development of revumenib and axatilimab, with topline data expected in the first half of 2023.

Syndax Pharmaceuticals reported its Q1 2022 financial results, with a net loss attributable to common stockholders of $37.2 million, or $0.63 per share. The company is advancing its pivotal programs for revumenib and axatilimab, with topline data expected starting in the first half of 2023.

Syndax Pharmaceuticals reported a net profit attributable to common stockholders of $96.2 million or $1.81 per share for the three months ended December 31, 2021. The company's pipeline development remains on track, with topline data expected from pivotal programs starting in the first half of 2023.

Syndax Pharmaceuticals reported its Q3 2021 financial results, highlighting the initiation of the pivotal Phase 2 portion of the SNDX-5613 AUGMENT-101 trial and a global collaboration with Incyte for axatilimab. Updated data from SNDX-5613 and axatilimab clinical programs will be presented at the ASH Annual Meeting.

Syndax Pharmaceuticals reported a net loss of $22.9 million, or $0.44 per share, for the second quarter of 2021. The company's research and development expenses increased to $16.9 million, while general and administrative expenses decreased to $5.8 million. As of June 30, 2021, Syndax had cash, cash equivalents and short-term investments of $253.1 million.

Syndax Pharmaceuticals reported a net loss attributable to common stockholders of $27.7 million, or $0.54 per share, for the first quarter ended March 31, 2021. As of March 31, 2021, Syndax had cash, cash equivalents and short-term investments of $271.3 million.

Syndax Pharmaceuticals reported a net loss of $20.4 million for the fourth quarter of 2020, with research and development expenses increasing to $15.5 million and general and administrative expenses decreasing to $4.7 million. The company's cash balance at the end of the year was $293.1 million, providing a cash runway into 2023.

Syndax Pharmaceuticals reported a net loss of $20.4 million, or $0.46 per share, for the third quarter of 2020. The company's research and development expenses increased to $14.4 million, and general and administrative expenses increased to $5.8 million. As of September 30, 2020, Syndax had $170.2 million in cash, cash equivalents and short-term investments.

Syndax Pharmaceuticals reported a net loss of $17.1 million, or $0.42 per share, for the second quarter of 2020. As of June 30, 2020, Syndax had cash, cash equivalents and short-term investments of $186.8 million.

Syndax Pharmaceuticals reported its Q1 2020 financial results, highlighting key data readouts expected across its portfolio, including the anticipation of the final overall survival readout from the E2112 trial and initial Phase 1 data from the AUGMENT-101 trial of SNDX-5613.

Syndax Pharmaceuticals reported its fourth quarter 2019 financial results. The company had $59.8 million in cash, cash equivalents and short-term investments as of December 31, 2019. Meaningful data readouts are expected for each of the pipeline candidates in 2020.